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Background: In type 2 diabetic patients, cardiac events in the perioperative period may be associated with
diminished myocardial vasomotor function and endothelial dysfunction. The influence of sevoflurane anaesthesia
on myocardial endothelial dysfunction in type 2 diabetic mellitus is investigated in this pilot study.
Methods: Six males with type 2 diabetes mellitus and eight healthy controls were included. Using myocardial
contrast echocardiography, myocardial blood flow (MBF) was measured at rest, during adenosine-induced
hyperaemia (endothelium-independent vasodilation) and after sympathetic stimulation by the cold pressor test
(endothelium-dependent vasodilation). Measurements were performed before and after induction of
sevoflurane anaesthesia.
Results: Sevoflurane anaesthesia decreased resting MBF in diabetics but not in controls (P = 0.03), while baseline
MBF did not differ between diabetics and controls. Without anaesthesia, adenosine-induced hyperaemia increased
MBF in both groups compared to resting values. Adenosine combined with sevoflurane resulted in a lower
hyperaemic MBF in both groups compared to no anaesthesia. Differences in MBF in response to adenosine before
and after sevoflurane administration were larger in diabetic patients, however not statistically significant in this pilot
group (P = 0.08). Myocardial blood flow parameters after the cold pressor test were not different between groups.
Conclusion: These pilot data in type 2 diabetic patients show that sevoflurane anaesthesia decreases resting myocardial
blood flow compared to healthy controls. Further, we observed a trend towards a lower endothelium-independent
vasodilation capacity in diabetic patients under sevoflurane anaesthesia. Endothelium-dependent vasodilation was not
affected by sevoflurane in diabetic patients. These data provide preliminary insight into myocardial responses in type 2
diabetic patients under general anaesthesia.
Trial registration: www.clinicialtrials.gov, NCT00866801
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Diabetes mellitus is a major risk factor for cardiovascular
morbidity and mortality [1]. In the perioperative period,
cardiovascular events such as myocardial ischemia are
more likely to occur in patients with diabetes mellitus
[2]. These perioperative cardiac events may be associated
with abnormalities in myocardial blood flow (MBF) due* Correspondence: c.bulte@vumc.nl
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unless otherwise stated.to endothelial dysfunction, an entity characterized by
an impaired ability of the resistance vessels to dilate, or
an enhanced response to vasoconstrictor agonists [3,4].
Hyperglycaemia is a major contributing factor in the
development of endothelial dysfunction in type 2 diabetes
[5,6]. Furthermore, impaired insulin signalling in endothe-
lial cells, dyslipidaemia and altered secretions of adipo-
kines from adipose tissue also have a detrimental role on
vascular function [7].
Myocardial endothelial function can be evaluated by
measuring vasodilator responses to sympathetic stimula-
tion (primarily endothelium-dependent vasodilation) andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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sine and dipyridamole (primarily endothelium-independent
vasodilation). Studies in humans with type 2 diabetes have
shown attenuation of myocardial responses to adenosine
and dipyridamole [8-10]. Also, progressive worsening
of the endothelium-dependent vasodilator capacity of
the myocardium with increasing insulin-resistance was
demonstrated in type 2 diabetic patients [8]. Myocardial
responses to sympathetic stimulation were even further
diminished in patients with an associated cardiac auto-
nomic neuropathy [9].
Sevoflurane is a frequently used volatile anaesthetic
with coronary vasodilating properties [11,12]. Experimental
studies showed preservation of myocardial perfusion during
sevoflurane anaesthesia if perfusion pressure was main-
tained [13-15]. Also, a study in isolated rat hearts reported
a decreased vasodilator response to adenosine during
sevoflurane administration [16]. Recently, we showed that
sevoflurane anaesthesia did not affect resting MBF in
cardiovascular healthy subjects. The vasodilator response
to adenosine (endothelium-independent vasodilation) was
diminished compared to measurement without anaesthe-
sia. Endothelium-dependent vasodilation was not affected
by sevoflurane. Human and experimental data on MBF
and endothelial function under general anaesthesia in type
2 diabetes mellitus are lacking.
We hypothesised that myocardial endothelial function
is affected by general anaesthesia in patients with type 2
diabetes mellitus. This pilot study was undertaken to
investigate how type 2 diabetic patients respond to myo-
cardial vasodilators under sevoflurane anaesthesia when
compared to healthy controls.
Methods
Participants
The local Human Subjects Ethics Committee of the VU
University Medical Center in Amsterdam, the Netherlands,
approved this study (ID 2008/304). Subsequent patients
were included after written informed consent. We pro-
spectively studied 6 patients with type 2 (non-insulin
dependent) diabetes mellitus and 8 healthy control sub-
jects, all scheduled for non-cardiac surgery under general
anaesthesia. Six out of 8 healthy volunteers were se-
lected based on sex from a previously published study
by Bulte et al. [17]. The diabetic subjects had haemoglobin
A1c levels of 6.8 ± 0.8% (range 5.5 – 7.6%) and fasting glu-
cose levels of 8.5 ± 1.5 mmol/l (range 6.7 – 10.9 mmol/l).
Mean duration of type 2 diabetes was 7.7 ± 5 year (range
3 – 15 years), diabetic patients only received oral antidia-
betic therapy. Exclusion criteria for participation included
age < 18 years, allergy to echocardiographic contrast agents
or adenosine, previous history of coronary artery disease,
chronic obstructive pulmonary disease and use of beta-
adrenergic blocking agents.Study protocol
All participants made an extra visit to our hospital for
screening, autonomic function testing and baseline myo-
cardial blood flow measurements. On the day of surgery
the MBF measurements were repeated after the induc-
tion of sevoflurane anaesthesia but before the start of
the surgical procedure.
Myocardial blood flow measurements
As previously described, transthoracic myocardial con-
trast echocardiography (MCE) was performed using an
iE33 ultrasound scanner equipped with a S5 – 1 trans-
ducer (Philips Medical Systems, Best, The Netherlands)
[18]. A contrast agent consisting of microbubbles filled
with sulphur hexafluoride with a mean diameter of 2,5 μm
was used (Sonovue, Bracco Imaging, Milan, Italy) and con-
tinuously infused using a specific syringe pump (VuEject,
Bracco SA, Switzerland). After two minutes of microbub-
ble infusion, baseline perfusion images were acquired
from apical 4-, 2- and 3-chamber views. Subsequently,
hyperaemia was induced by a continuous infusion of
0.14 mg kg−1 min−1 adenosine. Finally, sympathetic stimu-
lation was triggered by the cold pressor test (CPT) by im-
mersing the hand of the patient in ice water (2 – 4°C) for
3 minutes. Perfusion sequences were recorded and con-
sisted of 10 cardiac cycles of low acoustic power (mechan-
ical index [MI] 0.17) imaging for microbubble detection
followed by a burst of high acoustic power (MI 0.64) for
microbubble destruction. Subsequently, 20 cardiac cycles
were recorded with low MI imaging at a frame rate of
18 Hz to allow contrast replenishment in the myocardium.
All data were stored for offline analysis.
Evaluation of autonomic function
All subjects underwent a set of standard autonomic func-
tion tests to screen for cardiovascular autonomic neur-
opathy. First, subjects are placed in the supine position
and heart rate (R – R intervals) was recorded for 5 min
during spontaneous breathing. Subsequently, autonomi-
cally induced variations in R – R intervals to changes in
blood pressure were recorded during one minute of deep
breathing, during the Valsalva manoeuvre (Valsalva ratio)
and quick stand test. R – R intervals and blood pressure
were continuously recorded using a non-invasive con-
tinuous finger arterial blood pressure measurement de-
vice with a sample rate of 200 Hz (Nexfin HD, BMEYE,
Edwards Lifesciences, The Netherlands). Data was stored
on a personal computer for further analysis using free
available software (Kubios HRV version 2.0, University of
Kuopio, Finland and Beatscope, BMEYE, Edwards Life-
sciences, The Netherlands). During spontaneous breathing
over 5 minutes, heart rate variability (HRV) was assessed
by spectral analysis using fast Fourier transformation. This
method divides the overall variability of a signal into its
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extent a frequency contributes to the overall variability. The
power spectrum of HRV consists of three peaks: the very-
low-frequency band (<0.04 Hz), the low-frequency band
(0.04 – 0.12 Hz) and the high-frequency band (0.12 –
0.40 Hz). The very-low-frequency fluctuations mediated
primarily by the sympathetic system, the low-frequency
fluctuations by both the sympathetic and parasympathetic
system and the high-frequency fluctuations are under para-
sympathetic control.
From the recordings during deep breathing, maximum
and minimum R – R intervals were extracted and expressed
as a ratio, which in healthy subjects should be larger than
1.17. For the Valsalva manoeuvre, subjects exhaled forcibly
through a manometer against a pressure of 40 mmHg
for 15 s. The ratio of R – R intervals was calculated,
being > 1.21 in healthy subjects. Assessment of heart
rate response during quick standing, R – R intervals were
measured at 15 and 30 beats after standing. In healthy
subjects, the ratio of the longest R – R interval to the
shortest R – R interval is > 1.04. To assess changes in
blood pressure during standing, systolic blood pressure
was measured in the resting, supine subject. Two minutes
after rapid standing, the measurement was repeated. In
healthy subjects the fall in systolic blood pressure after the
test should be less than 10 mmHg. Cardiac autonomic
neuropathy is defined as the presence of 3 or more abnor-
mal test results among these 7 tests [19].
Anaesthesia
Heart rate, blood pressure and oxygen saturation were
monitored throughout the protocol. All patients received
midazolam 0.02 mg kg−1 intravenously. Anaesthesia was
induced by sevoflurane inhalation (AbbVie, Hoofddorp,
The Netherlands) and maintained at an age-adjusted
end-tidal concentration of 1.0 minimum alveolar con-
centration. A laryngeal mask airway was inserted and pa-
tients continued to breathe spontaneously without positive
airway pressure during the study period. The surgical pro-
cedure started after MBF measurements were completed.
Analysis of contrast echocardiography
Semiautomated software providing manual region of inter-
est (ROI) tracking, visualisation of perfusion calculations
and dataset handling was used (PerfusionFitter, Depart-
ment of Cardiology, Bern University Hospital). ROIs were
drawn in end-systolic frames in the mid-inferoseptal and
mid-anterolateral wall (apical 4-chamber view); in the mid-
inferior and mid-anterior wall (apical 2-chamber view) and
in the mid-inferolateral and mid-anteroseptal wall (apical
3-chamber view) of the myocardium. Using the volumetric
model by Vogel et al., myocardial blood flow was quanti-
fied in ml min−1 g−1 from the underlying microvascular pa-
rameters: (1) the relative myocardial blood volume, whichrepresents the blood volume in the capillary system, and
(2) the capillary exchange rate, which provides an estimate
of the exchange rate of erythrocytes within the region of
interest [20]. Changes in blood pressure and heart rate
during the interventions were monitored at regular inter-
vals. Additional calculations were made to provide an esti-
mate of myocardial oxygen consumption (rate-pressure
product [RPP]; heart rate x systolic blood pressure) and
coronary vascular resistance (CVR; dividing mean arterial
blood pressure by MBF).
Statistics
All data are presented as mean ± SD unless indicated
otherwise. Baseline characteristics between controls and
diabetics were compared using a Mann–Whitney U test.
A Wilcoxon signed-rank test was used for within group
comparisons of myocardial blood flow results (baseline
versus sevoflurane). Changes in myocardial blood flow
responses before and during sevoflurane administration
were compared between controls and diabetics using a
Mann–Whitney U test. Descriptive statistics were pro-




Table 1 shows baseline characteristics of the study popu-
lation. Eight cardiovascular healthy males and six dia-
betic males were included in this pilot study. Type 2
diabetic patients were older than control subjects. No
statistical difference in BMI is observed between groups.
Fasting glucose and HbA1c-levels were higher in patients
with type 2 diabetes. Further, total and LDL-cholesterol
levels were lower in diabetics.
Autonomic function
Clinical assessment of autonomic function in the control
group revealed no abnormal responses to the tests (Table 2).
In the diabetic group, one patient was identified with auto-
nomic dysfunction based on three abnormal test results
(heart rate response to deep breathing and standing, blood
pressure response to standing). One patient had two abnor-
mal responses (power spectrum in the low-frequency band
and heart rate response to deep breathing), indicating
borderline autonomic dysfunction.
Haemodynamics
At baseline, heart rate and RPP increased in both groups
during adenosine infusion (Table 3). These responses were
blunted in both groups during adenosine-induced hyper-
aemia under sevoflurane anaesthesia. The CPT at baseline
increased SBP and RPP in diabetics and controls. Under
sevoflurane anaesthesia, the CPT decreased SBP and RPP
Table 2 Results of autonomic function tests under
standardised conditions
Controls (N = 8) Diabetics (N = 6)




















0.12 – 0.40 Hz
Deep breathing 1.25 ± 0.08 1.19 ± 0.11
Heart rate response ratio
Valsalva maneuver 1.75 ± 0.27 1.56 ± 0.23
Heart rate response ratio
Quick stand 1.56 ± 0.29 1.31 ± 0.31
Heart rate response ratio






Data are presented as median (IQR [range]) or mean ± SD.





Age, years (range) 44 (28 – 59) 57 (42 – 71)*
BMI, kg/m2 25.7 ± 3.4 30.7 ± 9.4
Duration of diabetes (year) - 7.7 ± 5
Fasting blood glucose (mmol/l) 4.9 ± 0.4 8.5 ± 1.5*
HbA1c (%) 5.4 ± 0.2 6.8 ± 0.8*
Total cholesterol (mmol/l) 5.1 ± 0.8 3.7 ± 0.3*
LDL cholesterol (mmol/l) 3.1 ± 0.7 1.8 ± 0.3*
HDL cholesterol (mmol/l) 1.3 ± 0.5 1.2 ± 0.4
Triglycerides (mmol/l) 1.4 ± 0.8 2.5 ± 2.9
Creatinine (μmol/l) 83 ± 12 69 ± 10
Urea (mmol/l) 5.5 ± 0.8 5.0 ± 0.9







BMI: body mass index; LDL: low-density lipoprotein; HDL: high-density lipoprotein.
Data are represented as mean ± SD unless indicated otherwise; Mann–Whitney
U test, * p < 0.05.
Table 3 Descriptive statistics of haemodynamic parameters
at baseline and during sevoflurane anaesthesia
Controls (N = 8) Diabetics (N = 6)
Baseline Sevoflurane Baseline Sevoflurane
Rest
HR 62 ± 8 66 ± 12 71 ± 14 75 ± 16
SBP 111 ± 10 96 ± 17 128 ± 17 104 ± 16
DBP 76 ± 8 53 ± 12 76 ± 13 58 ± 20
RPP 6812 ± 816 6338 ± 1517 9209 ± 2814 7660 ± 1482
CVR 98 ± 27 76 ± 25 84 ± 12 106 ± 70
Hyperemia
HR 87 ± 15 78 ± 11 90 ± 7 77 ± 20
SBP 120 ± 14 80 ± 9 131 ± 24 90 ± 18
DBP 76 ± 5 44 ± 6 77 ± 17 49 ± 20
RPP 10450 ± 2225 6207 ± 1068 11890 ± 2840 6612 ± 1736
CVR 29 ± 5 26 ± 3 36 ± 12 66 ± 53
CPT
HR 67 ± 6 65 ± 13 78 ± 11 69 ± 13
SBP 131 ± 21 81 ± 6 152 ± 21 97 ± 9
DBP 80 ± 10 40 ± 9 88 ± 16 50 ± 12
RPP 8772 ± 1409 5208 ± 794 11920 ± 3082 6680 ± 999
CVR 70 ± 24 45 ± 6 95 ± 31 56 ± 49
Data are presented as mean ± SD, descriptive statistics. CPT = cold pressor test;
CVR = coronary vascular resistance (mmHg min g ml−1); DBP = diastolic blood
pressure (mmHg); HR = heart rate (min−1); RPP = rate pressure product
(min−1 mmHg); SBP = systolic blood pressure (mmHg).
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decreased in diabetics.
Myocardial blood flow measurements
Sevoflurane anaesthesia decreased MBF in diabetics but
not in controls (P = 0.03). At baseline, adenosine-induced
hyperaemia increased MBF in both groups compared to
resting values. However, when adenosine was combined
with sevoflurane anaesthesia, the MBF was significantly
lower in both controls and diabetics when compared to
baseline conditions (Figure 1). Differences in MBF re-
sponse to adenosine before and after sevoflurane adminis-
tration were larger in diabetic patients, this was however
not statistically significant in this pilot group (P = 0.08).
Myocardial blood flow parameters after the cold pressor
test were not different between groups at baseline and
during sevoflurane exposure.
Discussion
In this pilot study, we show that sevoflurane anaesthesia
impairs resting myocardial blood flow in type 2 diabetic
patients, while it preserves myocardial blood flow in healthy
controls. Furthermore, we observed a decrease in hyper-
aemic MBF (endothelium-independent vasodilation) during
Figure 1 (See legend on next page.)
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Figure 1 Myocardial blood flow measured with contrast echocardiography. Myocardial blood flow at rest (A) and after adenosine infusion
(B) and cold pressor testing (C) in healthy controls and diabetic patients. Dot plots indicate median ± range. CPT = cold pressor test; MBF =myocardial
blood flow. A Wilcoxon signed-rank test was used for within group comparisons of myocardial blood flow results (baseline versus sevoflurane). Changes
in myocardial blood flow responses before and during sevoflurane administration were compared between controls and diabetics using a
Mann–Whitney U test.
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wards a larger decrease in diabetic patients. Sympathetic
stimulation under sevoflurane did not lead to changes in
MBF in controls or diabetics when compared to baseline
(endothelium-dependent vasodilation). These findings sug-
gest different myocardial responses to sevoflurane anaesthe-
sia in type 2 diabetic patients compared to healthy controls.
Type 2 diabetes mellitus leads to endothelial dysfunction
of the coronary circulation due to reduced availability of
nitric oxide, accumulation of glycation end products in
the arterial wall, impaired insulin signalling, inflammation
and other still unknown mechanisms [7,21]. Picchi et al.
showed that diabetic coronary dysfunction is clinically
characterised by increased basal MBF and similar hyper-
aemic MBF compared to healthy patients [22]. In con-
trast, Di Carli et al. reported similar resting MBF and
lower hyperaemic MBF in diabetics compared to controls
[9]. The additional influence of sevoflurane anaesthesia on
MBF and endothelial function in diabetic patients is largely
unknown. Our type 2 diabetic patients had a lower resting
MBF when compared to baseline and this sevoflurane ef-
fect on MBF was different from healthy controls. Interest-
ingly, Cosyns et al. reported no difference in resting MBF
in streptozotocin-induced type 1 diabetic rats compared to
controls rats under thiopental anaesthesia [23]. No studies
on sevoflurane anaesthesia are available for comparison
with our data.
Sevoflurane anaesthesia decreased MBF during adenosine-
induced hyperaemia in both groups when compared to
baseline conditions. This was in accordance with our
previous study in healthy volunteers [17]. Also, diabetics
tended to have a larger decrease in MBF than healthy
controls. Cosyns et al., showing higher hyperaemic MBF
in controls than in diabetic rats, confirm the latter observa-
tion [23]. Underlying mechanisms for this observation may
include changes in perfusion pressure and myocardial
oxygen demand, decreased capillary recruitment in diabetic
myocardium and direct effect of sevoflurane on endothelial
cells [24].
Endothelial-dependent vasodilation by the CPT during
sevoflurane anaesthesia was not different from baseline
in both controls and diabetic patients. It has been shown
that the MBF response to sympathetic stimulation is pri-
marily dependent on the integrity of the autonomic nervous
system and not on hemodynamic changes or circulating
catecholamine levels [25]. Also, it was shown by the same
investigators that impaired MBF responses to endothelium-dependent vasodilation in type 2 diabetic patients were
related to the degree of cardiac autonomic dysfunction
[9]. In our population, only one out of six diabetic pa-
tients had clinical evidence of autonomic dysfunction,
which hampers evaluation of MBF responses in this sub-
population under sevoflurane anaesthesia. Future study
designs should also be aimed at type 2 diabetics with
cardiac autonomic dysfunction.
For this study sevoflurane anaesthesia was used since
it is widely available and allows both induction and
maintenance of anaesthesia. Volatile anaesthetics are
thought to possess cardioprotective properties although
experimental evidence suggests that these properties are
reduced in type 2 diabetes [26]. Interestingly, a recent
study reported that the widely used intravenous anaes-
thetic propofol attenuates hyperglycaemia-induced up-
regulation of endothelial adhesion molecules expression
and mononuclear-endothelial adhesion [27]. This implicates
that propofol inhibits pathological leukocytes-endothelial
adhesion and may subsequently prevent endothelial dys-
function and injury. Furthermore, comparing between sevo-
flurane and propofol, it has been reported that sevoflurane
better preserved right ventricular function than propofol in
patients receiving esophagectomy. However, propofol was
better in improving oxygenation and shunt-fraction during
one-lung ventilation [28]. The results of these studies sug-
gest that the choice of anaesthetic may be of interest in
certain patient categories. Specifically in type 2 diabetics,
influence of the two most widely used agents on myocar-
dial perfusion and function should be further investigated.
All type 2 diabetic patients in this study received oral
antidiabetic therapy (see Table 1), which are known to
exert cardiovascular effects and may affect myocardial
blood flow. Previous studies reported cardioprotective
effects exerted by metformin mediated by protein kinase
B, adenosine monophosphate-activated protein kinase and
upregulation of insulin signalling pathways [29,30]. Also,
metformin improved endothelium-dependent vasodilation
in both nondiabetic and diabetic subjects [31,32]. In
isolated rat hearts, sulfonylurea derivatives reduced
myocardial perfusion under ischemic conditions, while
perfusion under normal conditions was unaffected [33,34].
In humans, these oral diabetics deteriorated both resting
and hyperaemic myocardial blood flow [35]. In type 2 dia-
betic patients, exenatide increased myocardial blood flow,
while treatment with peroxisome proliferator-activated
gamma agonists did not affect myocardial perfusion
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the results of this study cannot be concluded.
The small number of patients studied limits interpret-
ation of the present study results. However, pilot studies
are valuable and necessary to enable power calculation for
future studies. Ideally, in subsequent studies age-matched
controls should be used for comparison with diabetic sub-
jects. The age difference between healthy controls and dia-
betic subjects in this study could be a potential confounder.
Already in this small study population we showed that
sevoflurane reduces resting MBF in diabetic patients
compared to healthy controls. Hyperaemic MBF decreased
during sevoflurane anaesthesia in both groups. Next, an
adequately powered study should be undertaken; for hyper-
aemia a sample size of 21 in each group will have 80%
power to detect a significant difference using a two-group
t-test with a 0.05 two-sided significance level. For cold
pressor testing, a sample size of 92 in each group will have
80% power to detect a significant difference using a
two-group t-test with a 0.05 two-sided significance level.
Furthermore, assessment of effects of hypo- and hyper-
insulinemia on vascular reactivity via nitric oxide and
insulin signaling proteins such as Akt and endothelial nitric
oxide synthase combined with altered plasma levels of
endothelin-1, asymmetric dimethylarginine and nitric oxide
may elucidate mechanisms behind sevoflurane-induced
MBF changes in diabetic patients [38-41].Conclusions
In conclusion, these pilot data suggest that sevoflurane
anaesthesia decreases resting myocardial blood flow in
type 2 diabetic patients compared to healthy controls. Fur-
ther, we observed a trend towards a lower endothelium-
independent vasodilation capacity in diabetic patients
under sevoflurane anaesthesia. These data provide prelim-
inary insight into myocardial responses in type 2 diabetic
patients under general anaesthesia.
Abbreviations
BMI: Body mass index; CPT: Cold pressor test; CVR: Coronary vascular
resistance; DBP: Diastolic blood pressure; HR: Heart rate; HRV: Heart rate
variability; HDL: High-density lipoprotein cholesterol; LDL: Low-density
lipoprotein cholesterol; MBF: Myocardial blood flow; MCE: Myocardial
contrast echocardiography; MI: Mechanical index; ROI: Region of interest;
RPP: Rate-pressure product; SBP: Systolic blood pressure.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CSEB participated in performing the study, data analysis, statistics and writing
of the manuscript. CEvdB supported the data analysis and writing of the
manuscript. SAL participated in the design of the study and reviewed/edited
the manuscript. CB participated in the design of the study, data analysis and
reviewed/edited the manuscript. RAB participated in the design of the study,
data collection and reviewed/edited the manuscript. All authors read and
approved the final manuscript.Acknowledgements
This work was supported by the Department of Anaesthesiology, VU
University Medical Center, Amsterdam, the Netherlands and a Dr. E. Dekker
research career grant of the Netherlands Heart foundation, The Hague, The
Netherlands (no. 2008T003) (RAB).
Author details
1Department of Anaesthesiology, Institute for Cardiovascular Research, VU
University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam,
The Netherlands. 2Laboratory for Physiology, Institute for Cardiovascular
Research, VU University Medical Center, Amsterdam, The Netherlands.
Received: 17 March 2014 Accepted: 20 March 2014
Published: 23 March 2014
References
1. Kannel WB, McGee DL: Diabetes and cardiovascular disease. The
Framingham study. JAMA 1979, 241:2035–2038.
2. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE,
Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC,
Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA,
Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW,
Nishimura R, Ornato JP, Page RL, Tarkington LG, et al: ACC/AHA 2007
guidelines on perioperative cardiovascular evaluation and care for
noncardiac surgery: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (Writing
Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular
Evaluation for Noncardiac Surgery): developed in collaboration with the
American Society of Echocardiography, American Society of Nuclear
Cardiology, Heart Rhythm Society, Society of Cardiovascular
Anesthesiologists, Society for Cardiovascular Angiography and
Interventions, Society for Vascular Medicine and Biology, and Society for
Vascular Surgery. Circulation 2007, 116:e418–e499.
3. Valenta I, Dilsizian V, Quercioli A, Schelbert HR, Schindler TH: The Influence
of Insulin Resistance, Obesity, and Diabetes Mellitus on Vascular Tone
and Myocardial Blood Flow. Curr Cardiol Rep 2011, 14:217–225.
4. Setty S, Sun W, Martinez R, Downey HF, Tune JD: Alpha-adrenoceptor-
mediated coronary vasoconstriction is augmented during exercise in
experimental diabetes mellitus. J Appl Physiol 2004, 97:431–438.
5. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases:
the role of oxidant stress. Circ Res 2000, 87:840–844.
6. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M,
Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG,
Forstermann U, Munzel T: Mechanisms underlying endothelial
dysfunction in diabetes mellitus. Circ Res 2001, 88:E14–E22.
7. Eringa EC, Serne EH, Meijer RI, Schalkwijk CG, Houben AJHM, Stehouwer CDA,
Smulders YM, van Hinsbergh VWM: Endothelial dysfunction in (pre)diabetes:
characteristics, causative mechanisms and pathogenic role in type 2
diabetes. Rev Endocr Metab Disord 2013, 14:39–48.
8. Prior JO, Quiñones MJ, Hernandez-Pampaloni M, Facta AD, Schindler TH,
Sayre JW, Hsueh WA, Schelbert HR: Coronary circulatory dysfunction in
insulin resistance, impaired glucose tolerance, and type 2 diabetes
mellitus. Circulation 2005, 111:2291–2298.
9. Di Carli MF, Bianco-Batlles D, Landa ME, Kazmers A, Groehn H, Muzik O,
Grunberger G: Effects of autonomic neuropathy on coronary blood flow
in patients with diabetes mellitus. Circulation 1999, 100:813–819.
10. Di Carli MF, Janisse J, Grunberger G, Ager J: Role of chronic hyperglycemia
in the pathogenesis of coronary microvascular dysfunction in diabetes.
J Am Coll Cardiol 2003, 41:1387–1393.
11. Bernard JM, Wouters PF, Doursout MF, Florence B, Chelly JE, Merin RG:
Effects of sevoflurane and isoflurane on cardiac and coronary dynamics
in chronically instrumented dogs. Anesthesiology 1990, 72:659–662.
12. Crystal GJ, Zhou X, Gurevicius J, Czinn EA, Salem MR, Alam S, Piotrowski A,
Hu G: Direct coronary vasomotor effects of sevoflurane and desflurane in
in situ canine hearts. Anesthesiology 2000, 92:1103–1113.
13. Conzen PF, Vollmar B, Habazettl H, Frink EJ, Peter K, Messmer K: Systemic
and regional hemodynamics of isoflurane and sevoflurane in rats.
Anesth Analg 1992, 74:79–88.
14. Hirano M, Fujigaki T, Shibata O, Sumikawa K: A comparison of coronary
hemodynamics during isoflurane and sevoflurane anesthesia in dogs.
Anesth Analg 1995, 80:651–656.
Bulte et al. Cardiovascular Diabetology 2014, 13:62 Page 8 of 8
http://www.cardiab.com/content/13/1/6215. Manohar M, Parks CM: Porcine systemic and regional organ blood flow
during 1.0 and 1.5 minimum alveolar concentrations of sevoflurane
anesthesia without and with 50% nitrous oxide. J Pharmacol Exp Ther
1984, 231:640–648.
16. Larach DR, Schuler HG: Direct vasodilation by sevoflurane, isoflurane, and
halothane alters coronary flow reserve in the isolated rat heart.
Anesthesiology 1991, 75:268–278.
17. Bulte CSE, Slikkerveer J, Kamp O, Heymans MW, Loer SA, de Marchi SF,
Vogel R, Boer C, Bouwman RA: General anesthesia with sevoflurane
decreases myocardial blood volume and hyperemic blood flow in
healthy humans. Anesth Analg 2013, 116:767–774.
18. Bulte CSE, Slikkerveer J, Meijer RI, Gort D, Kamp O, Loer SA, de Marchi SF,
Vogel R, Boer C, Bouwman RA: Contrast-enhanced ultrasound for
myocardial perfusion imaging. Anesth Analg 2012, 114:938–945.
19. Vinik AI, Ziegler D: Diabetic cardiovascular autonomic neuropathy.
Circulation 2007, 115:387–397.
20. Vogel R, Indermühle A, Reinhardt J, Meier P, Siegrist PT, Namdar M,
Kaufmann PA, Seiler C: The quantification of absolute myocardial
perfusion in humans by contrast echocardiography: algorithm and
validation. J Am Coll Cardiol 2005, 45:754–762.
21. Madonna R, De Caterina R: Cellular and molecular mechanisms of
vascular injury in diabetes–part I: pathways of vascular disease in
diabetes. Vascul Pharmacol 2011, 54:68–74.
22. Picchi A, Limbruno U, Focardi M, Cortese B, Micheli A, Boschi L, Severi S,
De Caterina R: Increased basal coronary blood flow as a cause of reduced
coronary flow reserve in diabetic patients. Am J Physiol Heart Circ Physiol
2011, 301:H2279–H2284.
23. Cosyns B, Droogmans S, Hernot S, Degaillier C, Garbar C, Weytjens C,
Roosens B, Schoors D, Lahoutte T, Franken PR, Van Camp G: Effect of
streptozotocin-induced diabetes on myocardial blood flow reserve
assessed by myocardial contrast echocardiography in rats. Cardiovasc
Diabetol 2008, 7:26.
24. Akata T, Izumi K, Nakashima M: The action of sevoflurane on vascular
smooth muscle of isolated mesenteric resistance arteries (part 2):
mechanisms of endothelium-independent vasorelaxation. Anesthesiology
2000, 92:1441–1453.
25. Di Carli MF, Tobes MC, Mangner T, Levine AB, Muzik O, Chakroborty P,
Levine TB: Effects of cardiac sympathetic innervation on coronary blood
flow. N Engl J Med 1997, 336:1208–1215.
26. van den Brom CE, Bulte CS, Loer SA, Bouwman RA, Boer C: Diabetes,
perioperative ischaemia and volatile anaesthetics: consequences of
derangements in myocardial substrate metabolism. Cardiovasc Diabetol
2013, 12:42.
27. Zhu M, Chen J, Jiang H, Miao C: Propofol protects against high glucose-
induced endothelial adhesion molecules expression in human umbilical
vein endothelial cells. Cardiovasc Diabetol 2013, 12:13.
28. Xu W-Y, Wang N, Xu H-T, Yuan H-B, Sun H-J, Dun C-L, Zhou S-Q, Zou Z,
Shi X-Y: Effects of sevoflurane and propofol on right ventricular function
and pulmonary circulation in patients undergone esophagectomy.
Int J Clin Exp Pathol 2014, 7:272–279.
29. El Messaoudi S, Rongen GA, de Boer RA, Riksen NP: The cardioprotective
effects of metformin. Curr Opin Lipidol 2011, 22:445–453.
30. Elmadhun NY, Lassaletta AD, Chu LM, Sellke FW: Metformin alters the
insulin signaling pathway in ischemic cardiac tissue in a swine model of
metabolic syndrome. J Thorac Cardiovasc Surg 2013, 145:258–265.
discussion 265–6.
31. Jadhav S, Ferrell W, Greer IA, Petrie JR, Cobbe SM, Sattar N: Effects of
metformin on microvascular function and exercise tolerance in women
with angina and normal coronary arteries: a randomized, double-blind,
placebo-controlled study. J Am Coll Cardiol 2006, 48:956–963.
32. Schindler TH, Facta AD, Prior JO, Cadenas J, Hsueh WA, Quinones MJ,
Schelbert HR: Improvement in coronary vascular dysfunction produced
with euglycaemic control in patients with type 2 diabetes. Heart 2007,
93:345–349.
33. Maruyama I, Tomiyama Y, Maruyama K, Ojima K, Kobayashi K, Kobayashi M,
Yamazaki Y, Kojima M, Shibata N: Effects of mitiglinide and sulfonylureas
in isolated canine coronary arteries and perfused rat hearts. Eur J
Pharmacol 2006, 531:194–200.
34. Legtenberg RJ, Houston RJF, Heerschap A, Oeseburg B, Smits P:
Glibenclamide attenuates ischemia-induced acidosis and loss of cardiac
function in rats. Eur J Pharmacol 2002, 434:35–42.35. Pop-Busui R, Oral E, Raffel D, Byun J, Bajirovic V, Vivekanandan-Giri A, Kellogg A,
Pennathur S, Stevens MJ: Impact of rosiglitazone and glyburide on nitrosative
stress and myocardial blood flow regulation in type 2 diabetes mellitus.
Metab Clin Exp 2009, 58:989–994.
36. Gejl M, Søndergaard HM, Stecher C, Bibby BM, Møller N, Bøtker HE, Hansen SB,
Gjedde A, Rungby J, Brock B: Exenatide alters myocardial glucose transport
and uptake depending on insulin resistance and increases myocardial blood
flow in patients with type 2 diabetes. J Clin Endocrinol Metab 2012,
97:E1165–E1169.
37. McMahon GT, Plutzky J, Daher E, Bhattacharyya T, Grunberger G, DiCarli MF:
Effect of a peroxisome proliferator-activated receptor-gamma agonist on
myocardial blood flow in type 2 diabetes. Diabetes Care 2005, 28:1145–1150.
38. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P: Nitric oxide
release accounts for insulin's vascular effects in humans. J Clin Invest
1994, 94:2511–2515.
39. Georgescu A, Popov D, Constantin A, Nemecz M, Alexandru N, Cochior D,
Tudor A: Dysfunction of human subcutaneous fat arterioles in obesity
alone or obesity associated with Type 2 diabetes. Clin Sci 2011,
120:463–472.
40. de Boer MP, Meijer RI, Newman J, Stehouwer CDA, Eringa EC, Smulders YM,
Serne EH: Insulin-induced changes in microvascular vasomotion and
capillary recruitment are associated in humans. Microcirculation. In press.
41. Wang T-D, Chen W-J, Cheng W-C, Lin J-W, Chen M-F, Lee Y-T: Relation of
improvement in endothelium-dependent flow-mediated vasodilation
after rosiglitazone to changes in asymmetric dimethylarginine,
endothelin-1, and C-reactive protein in nondiabetic patients with the
metabolic syndrome. Am J Cardiol 2006, 98:1057–1062.
doi:10.1186/1475-2840-13-62
Cite this article as: Bulte et al.: Myocardial blood flow under general
anaesthesia with sevoflurane in type 2 diabetic patients:
a pilot study. Cardiovascular Diabetology 2014 13:62.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
